HC Wainwright & Co. analyst Emily Bodnar downgrades SQZ Biotechnologies (NYSE:SQZ) from Buy to Neutral.
Amylyx Pharmaceuticals Announces First Participant Dosed In The Global Phase 3 ORION Study Of AMX0035 In Progressive Supranuclear Palsy
- Largest ever PSP clinical trial will evaluate the efficacy and safety of AMX0035 in adults with PSP compared to placebo- Trial to enroll approximately 600 participants across the U.S., Canada, Europe, and JapanAmylyx
